Bladder cancer subtypes defined by genomic alterations

References

• Lopez-Beltran A. Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol 2008; 42(Suppl 218)95–109
   Google Scholar
• Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 2006; 27: 361–73
   PubMed Web of Science ®Google Scholar
• Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 5: 713–25
   PubMed Web of Science ®Google Scholar
• Gibas Z, Prout GR, Jr, Connolly JG, Pontes JE, Sandberg AA. Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res 1984; 44: 1257–64
   PubMed Web of Science ®Google Scholar
• Fadl-Elmula I, Gorunova L, Mandahl N, Elfving P, Lundgren R, Mitelman F, et al. Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chromosomes Cancer 2000; 29: 256–65
   PubMed Web of Science ®Google Scholar
• Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 1993; 8: 1083–5
   PubMed Web of Science ®Google Scholar
• Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 1990; 50: 44–7
   PubMed Web of Science ®Google Scholar
• Linnenbach AJ, Pressler LB, Seng BA, Simmel BS, Tomaszewski JE, Malkowicz SB. Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay. Hum Mol Genet 1993; 2: 1407–11
   PubMed Web of Science ®Google Scholar
• Simoneau M, Aboulkassim TO, LaRue H, Rousseau F, Fradet Y. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene 1999; 18: 157–63
   PubMed Web of Science ®Google Scholar
• van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, van der Kwast TH, Zwarthoff EC. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 2000; 9: 2973–80
   PubMed Web of Science ®Google Scholar
• Louhelainen J, Wijkstrom H, Hemminki K. Initiation-development modelling of allelic losses on chromosome 9 in multifocal bladder cancer. Eur J Cancer 2000; 36: 1441–51
   PubMed Web of Science ®Google Scholar
• van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, Zwarthoff EC. The random development of LOH on chromosome 9q in superficial bladder cancers. J Pathol 2002; 198: 352–8
   PubMed Web of Science ®Google Scholar
• Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265: 415–7
   PubMed Web of Science ®Google Scholar
• Devlin J, Keen AJ, Knowles MA. Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA. Oncogene 1994; 9: 2757–60
   PubMed Web of Science ®Google Scholar
• Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995; 87: 1524–9
   PubMed Web of Science ®Google Scholar
• Williamson MP, Elder PA, Shaw ME, Devlin J, Knowles MA. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 1995; 4: 1569–77
   PubMed Web of Science ®Google Scholar
• Berggren P, Kumar R, Sakano S, Hemminki L, Wada T, Steineck G, et al. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res 2003; 9: 235–42
   PubMed Web of Science ®Google Scholar
• Chapman EJ, Harnden P, Chambers P, Johnston C, Knowles MA. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res 2005; 11: 5740–7
   PubMed Web of Science ®Google Scholar
• Bartoletti R, Cai T, Nesi G, Roberta Girardi L, Baroni G, Dal Canto M. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J Surg Res 2007; 143: 422–7
   PubMed Web of Science ®Google Scholar
• Berggren de Verdier PJ, Kumar R, Adolfsson J, Larsson P, Norming U, Onelov E, et al. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer. Scand J Urol Nephrol 2006; 40: 363–9
   PubMed Web of Science ®Google Scholar
• Aboulkassim TO, LaRue H, Lemieux P, Rousseau F, Fradet Y. Alteration of the PATCHED locus in superficial bladder cancer. Oncogene 2003; 22: 2967–71
   PubMed Web of Science ®Google Scholar
• McGarvey TW, Maruta Y, Tomaszewski JE, Linnenbach AJ, Malkowicz SB. PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene 1998; 17: 1167–72
   PubMed Web of Science ®Google Scholar
• Habuchi T, Luscombe M, Elder PA, Knowles MA. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32–q33. Genomics 1998; 48: 277–88
   PubMed Web of Science ®Google Scholar
• Nishiyama H, Hornigold N, Davies A, Knowles M. A sequence-ready 840-kb PAC contig spanning the candidate tumor suppressor locus DBC1 on human chromosome 9q32–q33. Genomics 1999; 59: 335–8
   PubMed Web of Science ®Google Scholar
• Stadler WM, Steinberg G, Yang X, Hagos F, Turner C, Olopade OI. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res 2001; 7: 1676–82
   PubMed Web of Science ®Google Scholar
• Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 2003 2003; 63: 7652–6
   Google Scholar
• Hornigold N, Devlin J, Davies AM, Aveyard JS, Habuchi T, Knowles MA. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 1999; 18: 2657–61
   PubMed Web of Science ®Google Scholar
• Adachi H, Igawa M, Shiina H, Urakami S, Shigeno K, Hino O. Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. J Urol 2003; 17: 601–4
   Google Scholar
• Habuchi T, Yoshida O, Knowles MA. A novel candidate tumour suppressor locus at 9q32–33 in bladder cancer: localisation of the candidate region within a single 840kb YAC. Hum Mol Genet 1997; 6: 913–9
   PubMed Web of Science ®Google Scholar
• Nishiyama H, Takahashi T, Kakehi Y, Habuchi T, Knowles MA. Homozygous deletion at the 9q32–33 candidate tumor suppressor locus in primary human bladder cancer. Genes Chromosomes Cancer 1999; 26: 171–5
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Emi M, Nagai H, Ohgaki K, Imoto I, Akimoto M, et al. Definition of a 1-Mb homozygous deletion at 9q32–q33 in a human bladder-cancer cell line. J Hum Genet 2001; 46: 372–7
   PubMed Web of Science ®Google Scholar
• Habuchi T, Takahashi T, Kakinuma H, Wang L, Tsuchiya N, Satoh S, et al. Hypermethylation at 9q32–33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 2001; 20: 531–7
   PubMed Web of Science ®Google Scholar
• Salem C, Liang G, Tsai YC, Coulter J, Knowles MA, Feng AC, et al. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res 2000; 60: 2473–6
   PubMed Web of Science ®Google Scholar
• Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 2003; 63: 7652–6
   PubMed Web of Science ®Google Scholar
• Pymar LS, Platt FM, Askham JM, Morrison EE, Knowles MA. Bladder tumour derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Hum Mol Genet 2008;17:2006–2017.
   Google Scholar
• Hirao S, Hirao T, Marsit CJ, Hirao Y, Schned A, Devi-Ashok T, et al. Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer. Cancer 2005; 104: 1918–23
   PubMed Web of Science ®Google Scholar
• Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006; 25: 2685–96
   PubMed Web of Science ®Google Scholar
• Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet Y. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene 2000; 19: 6317–23
   PubMed Web of Science ®Google Scholar
• Edwards J, Duncan P, Going JJ, Watters AD, Grigor KM, Bartlett JM. Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J Pathol 2002; 196: 380–5
   PubMed Web of Science ®Google Scholar
• Keen AJ, Knowles MA. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 1994; 9: 2083–8
   PubMed Web of Science ®Google Scholar
• Ruppert JM, Tokino K, Sidransky D. Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 1993; 53: 5093–5
   PubMed Web of Science ®Google Scholar
• Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23: 18–20
   PubMed Web of Science ®Google Scholar
• Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001; 158: 1955–9
   PubMed Web of Science ®Google Scholar
• Sibley K, Stern P, Knowles MA. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 2001; 20: 4416–8
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61: 1265–8
   PubMed Web of Science ®Google Scholar
• Tomlinson D, Baldo O, Harnden P, Knowles M. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007; 213: 91–8
   PubMed Web of Science ®Google Scholar
• Zieger K, Dyrskjot L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005; 11: 7709–19
   PubMed Web of Science ®Google Scholar
• Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005; 24: 5218–25
   PubMed Web of Science ®Google Scholar
• Lopez-Knowles E, Hernandez S, Malats N, Kogevinas M, Lloreta J, Carrato A, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006; 66: 7401–4
   PubMed Web of Science ®Google Scholar
• Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994; 370: 527–32
   PubMed Web of Science ®Google Scholar
• Ramjaun AR, Downward J. Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis. Cell Cycle 2007; 6: 2902–5
   PubMed Web of Science ®Google Scholar
• Zhao J, Richter J, Wagner U, Roth B, Schraml P, Zellweger T, et al. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res 1999; 59: 4658–61
   PubMed Web of Science ®Google Scholar
• Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, Gasser TC, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997; 57: 2860–4
   PubMed Web of Science ®Google Scholar
• Hoque MO, Lee CC, Cairns P, Schoenberg M, Sidransky D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 2003; 63: 2216–22
   PubMed Web of Science ®Google Scholar
• Koed K, Wiuf C, Christensen LL, Wikman FP, Zieger K, Moller K, et al. High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 2005; 65: 34–45
   PubMed Web of Science ®Google Scholar
• Primdahl H, Wikman FP, von der Maase H, Zhou XG, Wolf H, Orntoft TF. Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst 2002; 94: 216–23
   PubMed Web of Science ®Google Scholar
• Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005; 11: 7012
   PubMed Web of Science ®Google Scholar
• Hopman AH, Kamps MA, Speel EJ, Schapers RF, Sauter G, Ramaekers FC. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Am J Pathol 2002; 161: 1119–25
   PubMed Web of Science ®Google Scholar
• Spruck CH, III, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784–8
   PubMed Web of Science ®Google Scholar
• Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 1995; 55: 5213–6
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992; 52: 1393–8
   PubMed Web of Science ®Google Scholar
• Uchida T, Wada C, Ishida H, Wang C, Egawa S, Yokoyama E, et al. p53 mutations and prognosis in bladder tumors. J Urol 1995; 153: 1097–104
   PubMed Web of Science ®Google Scholar
• Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607–14
   PubMed Web of Science ®Google Scholar
• Simon R, Struckmann K, Schraml P, Wagner U, Forster T, Moch H, et al. Amplification pattern of 12q13–q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 2002; 21: 2476–83
   PubMed Web of Science ®Google Scholar
• Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90: 1072–9
   PubMed Web of Science ®Google Scholar
• George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 2007; 25: 5352–8
   PubMed Web of Science ®Google Scholar
• Cairns P, Proctor AJ, Knowles MA. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 1991; 6: 2305–9
   PubMed Web of Science ®Google Scholar
• Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999; 18: 1197–203
   PubMed Web of Science ®Google Scholar
• Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004; 22: 1014–24
   PubMed Web of Science ®Google Scholar
• Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22: 1007–13
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84: 1251–6
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Xu H-J, Ro JY, Hu S-X, Sahin A, Ordonez N, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992; 84: 1256–61
   PubMed Web of Science ®Google Scholar
• Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 2008; 27: 2716–27
   PubMed Web of Science ®Google Scholar
• Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 2004; 23: 1627–30
   PubMed Web of Science ®Google Scholar
• Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004; 23: 5616–23
   PubMed Web of Science ®Google Scholar
• Oeggerli M, Schraml P, Ruiz C, Bloch M, Novotny H, Mirlacher M, et al. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene 2006; 25: 6538–43
   PubMed Web of Science ®Google Scholar
• Olsson AY, Feber A, Edwards S, Te Poele R, Giddings I, Merson S, et al. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene 2007; 26: 1028–37
   PubMed Web of Science ®Google Scholar
• Xu HJ, Cairns P, Hu SX, Knowles MA, Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 1993; 53: 781–4
   PubMed Web of Science ®Google Scholar
• Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999; 80: 904–8
   PubMed Web of Science ®Google Scholar
• Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 1997; 14: 3059–66
   PubMed Web of Science ®Google Scholar
• Kagan J, Liu J, Stein JD, Wagner SS, Babkowski R, Grossman BH, et al. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene 1998; 16: 909–13
   PubMed Web of Science ®Google Scholar
• Tsuruta H, Kishimoto H, Sasaki T, Horie Y, Natsui M, Shibata Y, et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 2006; 66: 8389–96
   PubMed Web of Science ®Google Scholar
• Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991; 63: 601–8
   PubMed Web of Science ®Google Scholar
• Lonn U, Lonn S, Friberg S, Nilsson B, Silfversward C, Stenkvist B. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995; 1: 1189–94
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Kubota Y, Noguchi S, Takase K, Matsuzaki J, Moriyama M, et al. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 2000; 55: 679–83
   PubMed Web of Science ®Google Scholar
• Sauter G, Moch H, Moore D, Carroll P, Kerschmann R, Chew K, et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 1993; 53(10 Suppl)2199–203
   PubMed Web of Science ®Google Scholar
• Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 2003; 107: 764–72
   PubMed Web of Science ®Google Scholar
• Hovey RM, Chu L, Balazs M, DeVries S, Moore D, Sauter G, et al. Genetic alterations in primary bladder cancers and their metastases. Cancer Res 1998; 58: 3555–60
   PubMed Web of Science ®Google Scholar
• Simon R, Burger H, Semjonow A, Hertle L, Terpe HJ, Bocker W. Patterns of chromosomal imbalances in muscle invasive bladder cancer. Int J Oncol 2000; 17: 1025–9
   PubMed Web of Science ®Google Scholar
• Veltman JA, Fridlyand J, Pejavar S, Olshen AB, Korkola JE, DeVries S, et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003; 63: 2872–80
   PubMed Web of Science ®Google Scholar
• Simon R, Eltze E, Schafer KL, Burger H, Semjonow A, Hertle L, et al. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res 2001; 61: 355–62
   PubMed Web of Science ®Google Scholar
• Richter J, Beffa L, Wagner U, Schraml P, Gasser TC, Moch H, et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 1998 1998; 153: 1615–21
   Google Scholar
• Schaffer AA, Simon R, Desper R, Richter J, Sauter G. Tree models for dependent copy number changes in bladder cancer. Int J Oncol 2001; 18: 349–54
   PubMed Web of Science ®Google Scholar
• Adams J, Williams SV, Aveyard JS, Knowles MA. Loss of heterozygosity analysis and DNA copy number measurement on 8p in bladder cancer reveals two mechanisms of allelic loss. Cancer Res 2005; 65: 66–75
   PubMed Web of Science ®Google Scholar
• Choi C, Kim MH, Juhng SW, Oh BR. Loss of heterozygosity at chromosome segments 8p22 and 8p11.2–21.1 in transitional-cell carcinoma of the urinary bladder. Int J Cancer 2000; 86: 501–5
   PubMed Web of Science ®Google Scholar
• Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004; 16: 465–78
   Google Scholar
• Takle LA, Knowles MA. Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene 1996; 12: 1083–7
   PubMed Web of Science ®Google Scholar
• Richter J, Wagner U, Schraml P, Maurer R, Alund G, Knonagel H, et al. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. Cancer Res 1999; 59: 5687–91
   PubMed Web of Science ®Google Scholar
• Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Jaramillo R, Amoros A, et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 2005; 11: 5444–50
   PubMed Web of Science ®Google Scholar
• Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003; 63: 8108–12
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boeve ER, Jobsis AC, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004; 64: 1911–4
   PubMed Web of Science ®Google Scholar
• Lopez-Knowles E, Hernandez S, Kogevinas M, Lloreta J, Amoros A, Tardon A, et al. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 2006; 12: 6029–36
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003; 21: 1912–21
   PubMed Web of Science ®Google Scholar
• Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 1998; 58: 5835–41
   PubMed Web of Science ®Google Scholar
• Hoglund M, Sall T, Heim S, Mitelman F, Mandahl N, Fadl-Elmula I. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. Cancer Res 2001; 61: 8241–6
   PubMed Web of Science ®Google Scholar
• Bulashevska S, Szakacs O, Brors B, Eils R, Kovacs G. Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data. Int J Cancer 2004; 110: 850–6
   PubMed Web of Science ®Google Scholar
• Hoglund M, Frigyesi A, Sall T, Gisselsson D, Mitelman F. Statistical behavior of complex cancer karyotypes. Genes Chromosomes Cancer 2005; 42: 327–41
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002; 198: 245–51
   PubMed Web of Science ®Google Scholar
• Sung MT, Maclennan GT, Lopez-Beltran A, Montironi R, Cheng L. Natural history of urothelial inverted papilloma. Cancer 2006; 107: 2622–7
   PubMed Web of Science ®Google Scholar
• Sung MT, Eble JN, Wang M, Tan PH, Lopez-Beltran A, Cheng L. Inverted papilloma of the urinary bladder: a molecular genetic appraisal. Mod Pathol 2006; 19: 1289–94
   PubMed Web of Science ®Google Scholar
• Eiber M, van Oers JM, Zwarthoff EC, van der Kwast TH, Ulrich O, Helpap B, et al. Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. Am J Surg Pathol 2007; 31: 938–46
   PubMed Web of Science ®Google Scholar
• Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999; 154: 721–7
   PubMed Web of Science ®Google Scholar
• Obermann EC, Junker K, Stoehr R, Dietmaier W, Zaak D, Schubert J, et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 2003; 199: 50–7
   PubMed Web of Science ®Google Scholar
• van Oers JM, Adam C, Denzinger S, Stoehr R, Bertz S, Zaak D, et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 2006; 119: 1212–5
   PubMed Web of Science ®Google Scholar
• Muto S, Horie S, Takahashi S, Tomita K, Kitamura T. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res 2000; 60: 4021–5
   PubMed Web of Science ®Google Scholar
• Knowles MA, Williamson M. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res 1993; 53: 133–9
   PubMed Web of Science ®Google Scholar
• Ooi A, Herz F, Ii S, Cordon-Cardo C, Fradet Y, Mayall BH, et al. Ha-ras codon 12 mutation in papillary tumors of the urinary bladder: a retrospective study. Int J Oncol 1994; 4: 85–90
   PubMed Web of Science ®Google Scholar
• Fitzgerald JM, Ramchurren N, Rieger K, Levesque P, Silverman M, Libertino JA, et al. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst 1995; 87: 129–33
   PubMed Web of Science ®Google Scholar
• Sibley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001; 20: 686–91
   PubMed Web of Science ®Google Scholar
• Proctor AJ, Coombs LM, Cairns JP, Knowles MA. Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene 1991; 6: 789–95
   PubMed Web of Science ®Google Scholar
• Bringuier PP, Tamimi J, Schuuring E. Amplification of the chromosome 11q13 region in bladder tumours. Urol Res 1994; 21: 451
   Google Scholar
• Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu W-J, et al. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 1994; 86: 1331–5
   PubMed Web of Science ®Google Scholar
• Lianes P, Orlow I, Zhang Z-F, Oliva MR, Sarkis AS, Reuter VE, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994; 86: 1325–30
   PubMed Web of Science ®Google Scholar
• Cairns P, Tokino K, Eby Y, Sidransky D. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 1994; 54: 1422–4
   PubMed Web of Science ®Google Scholar
• Shaw ME, Knowles MA. Deletion mapping of chromosome 11 in carcinoma of the bladder. Genes Chromosomes Cancer 1995; 13: 1–8
   PubMed Web of Science ®Google Scholar
• Sato K, Moriyama M, Mori S, Saito M, Watanuki K, Terada E, et al. An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992; 70: 2493–8
   PubMed Web of Science ®Google Scholar
• Sauter G, Moch H, Moore D, Carroll P, Kerchmann R, Chew K, et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 1993; 53: 2199–203
   PubMed Web of Science ®Google Scholar
• Zaharieva BM, Simon R, Diener PA, Ackermann D, Maurer R, Alund G, et al. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol 2003; 201: 603–8
   PubMed Web of Science ®Google Scholar
• Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999; 80: 904–8
   PubMed Web of Science ®Google Scholar
• Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998; 16: 3215–8
   PubMed Web of Science ®Google Scholar
• Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 1997; 14: 3059–66
   PubMed Web of Science ®Google Scholar
• Wang DS, Rieger-Christ K, Latini JM, Moinzadeh A, Stoffel J, Pezza JA, et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int J Cancer 2000; 88: 620–5
   PubMed Web of Science ®Google Scholar
• Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura K, et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 1993; 53: 3795–9
   PubMed Web of Science ®Google Scholar
• Sidransky D, von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252: 706–9
   PubMed Web of Science ®Google Scholar
• Spruck CH, Rideout WM, Olumi AF, Ohnesit PF, Yang AS, Tsai YC, et al. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res 1993; 53: 1162–6
   PubMed Web of Science ®Google Scholar